Expert Interview
Discussing the Phase 1/2 study of the ALK2 inhibitor zilurgisertib as a monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis
Ticker(s): INCYInstitution: MD Anderson
- Associate Professor of Medicine, Department of Leukemia at MD Anderson.
- Manages 40 patients with systemic mastocytosis.
- Research focus is on myeloproliferative neoplasms (MPNs). Heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research; leads number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis (PI on APEX, SUMMIT, HARBOR).
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
